STING1 and neoplasm: Through synergistic SDT‐induced antigen release and STING pathway activation, RCM‐Lip reshaped the TME, increasing in vivo tumor inhibition rate to 73.5%, providing a novel strategy for LC precision immunotherapy.[412] In SDT combined with ICB therapy, a study reported iron‐based micelle NMs (loaded with IR‐780 dye and surface‐modified with cyclic RGD) that activate ICD through ultrasound and combine with anti‐PD‐L1 checkpoint blockade.